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Abstract
Background: Coeliac disease (CD) is a common and complex disorder of the small intestine caused by intolerance
to wheat gluten and related edible cereals like barley and rye. Peptides originating from incomplete gliadin
digestion activate the lamina propria infiltrating T cells to release proinflammatory cytokines, which in turn cause
profound tissue remodelling of the small intestinal wall. There is no cure for CD except refraining from consuming
gluten-containing products.
Results: Phage from a random oligomer display library were enriched by repeated pannings against immobilised
gliadin proteins. Phage from the final panning round were plated, individual plaques picked, incubated with host
bacteria, amplified to a population size of 1011 to 1012 and purified. DNA was isolated from 1000 purified phage
populations and the region covering the 36 bp oligonucleotide insert from which the displayed peptides were
translated, was sequenced. Altogether more than 150 different peptide-encoding sequences were identified, many
of which were repeatedly isolated under various experimental conditions. Amplified phage populations, each
expressing a single peptide, were tested first in pools and then one by one for their ability to inhibit binding of
human anti-gliadin antibodies in ELISA assays. These experiments showed that several of the different peptide-
expressing phage tested inhibited the interaction between gliadin and anti-gliadin antibodies. Finally, four different
peptide-encoding sequences were selected for further analysis, and the corresponding 12-mer peptides were
synthesised in vitro. By ELISA assays it was demonstrated that several of the peptides inhibited the interaction
between gliadin molecules and serum anti-gliadin antibodies. Moreover, ELISA competition experiments as well as
dot-blot and western blot revealed that the different peptides interacted with different molecular sites of gliadin.
Conclusions: We believe that several of the isolated and characterised gliadin-binding peptides described here
could provide valuable tools for researchers in the field of CD by facilitating studies on localisation and uptake of
various gliadin peptides in the small intestine. In future work, the potential of these peptides to detoxify gluten will
be investigated.
Background
Coeliac disease (CD) is a common and complex inflam-
matory disorder of the small intestine that affects
genetically susceptible individuals carrying HLA-DQ2 or
-DQ8 haplotypes. Symptoms develop after ingestion of
gluten storage proteins (prolamins) from wheat (glia-
dins), barley (hordeins), rye (secalins), and their
crossbred varieties [1,2]. CD can be diagnosed at any
age. It can either be asymptomatic or present with a
broad spectrum of clinical manifestations. The classical
(typical) form of CD is usually characterized by gastroin-
testinal symptoms like flatulence, vomiting, constipation
or persistent diarrhoea, general failure to thrive, mineral
and vitamin deficiencies, and weight loss due to malab-
sorption. Atypical forms, on the other hand, present
predominantly with extra-intestinal manifestations that
include a blistering skin disease (Dermatitis herpetifor-
mis), iron-deficiency anaemia, osteoporosis, fatigue and
neurological complaints [3-6]. The prevalence of CD is
estimated to be about 1% in the Western populations
[7,8]. Moreover, in recent years the total disease preva-
lence has increased. The reason for the observed raise is
currently unknown and cannot be explained by the
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increase of CD diagnosis that occurred after introduc-
tion of antibody screening [9,10].
In CD patients, peptides that originate from incom-
plete digestion of gluten prolamins, either in their native
form or deamidated by tissue transglutaminase (tTG),
bind to HLA-DQ2 or -DQ8 receptors of antigen pre-
senting cells that activate the lamina propria infiltrating
CD4+ T cells. As a response the CD4+ T cells release
pro-inflammatory cytokines, in particular g-interferon.
Ultimately, this leads to profound tissue remodelling
characterised by the atrophy of the small intestinal villi
and hyperplasia of crypts [2,11-14]. Active CD is also
characterised by high levels of antibodies against tTG
and gliadin in the patients’ sera. The role of anti-tTG
IgA class antibodies is still unclear. However, it has
been proposed that they may be involved in the devel-
opment of mucosal damage [15]. Also IgG class anti-
gliadin antibodies have been shown to contribute to the
pathogenesis by activating the complement system or
inducing antibody-mediated cytotoxicity [16].
T cell epitopes in wheat gluten proteins have been
characterised within both gliadins and glutenins. A hier-
archy exists within these epitopes. The majority of CD
patient-derived intestinal T cell clones recognise a-glia-
dins, and less frequently g-gliadins and glutenins
[17-20]. The most prominent peptide is a 33-mer of a-
gliadins (residues 57-89) that contains six T-cell epi-
topes. Another fragments, also found in a-gliadins (resi-
dues 31-43 and 44-55), seem to be important for the
activation of the innate immunity system [18,21-23]. In
a recent study gluten-specific T cells from peripheral
blood of CD patients challenged either with wheat, bar-
ley, rye or a combination of the three cereals were used
to identify the immunostimulatory sequences in these
grains [24]. The a-gliadin 33-mer was found immuno-
genic only after the wheat challenge while seque-
nces from ω-gliadin (wheat) and C-hordein (barley)
were found to be immunodominant despite the grain
consumed.
Currently there is no cure for CD. The only existing
therapy is a life-long adherence to a gluten-free (GF)
diet [3]. However, several strategies that may in the
future serve as alternatives to the GF diet have been
proposed. T cell activation may be inhibited by mole-
cules that block peptide binding to HLA-DQ2. Alterna-
tively, inhibition of tissue transglutaminase may prevent
gluten deamidation [25]. Supplementation with prolyl
endopeptidases (PEPs), enzymes derived from moulds
and bacterial strains, or with a mixture of PEP and
cysteine endoprotease from germinating barley, which
aid in digestion of immunostimulatory gluten peptides
into harmless molecules, is under investigation [26-29].
Another possible therapeutic alternative that is currently
pursued is a vaccine that contains a mixture of
immunodominant peptides that trigger the immune
response and are supposed to retrain the immune sys-
tem of HLA-DQ2 positive CD subjects to tolerate gluten
[24,30]. Furthermore, an inhibitor of paracellular perme-
ability (AT-1001, larazotide acetate) has been shown to
reduce the intestinal barrier dysfunction, production of
pro-inflammatory cytokines, and GI symptoms in CD
individuals after gluten exposure [31,32]. Moreover,
attempts have been made to degrade toxic gluten
sequences during sourdough fermentation with selected
lactobacilli strains [33]. Finally, the potential of a linear
polymeric binder P(HEMA-co-SS) to neutralise gliadin
in vitro and in vivo in mice models have been described
[34]. Another alternative could be blocking gliadin
domains with synthetic peptides and thus preventing
tTG modification and formation of immunostimulatory
epitopes.
In the present study we have selected in vitro gliadin-
binding peptides with the help of phage display. Phage
display refers to a molecular method where gene
libraries are constructed in filamentous bacteriophage in
a way that each individual phage in the population will
display a unique peptide or protein on its surface [35].
From such a population, phage that interact with in
principle any a priori chosen molecule can be isolated
and amplified. The concept has been used in many dif-
ferent variations to select and produce novel peptides
that bind to target molecules of interest [36-38]. The
aim of this work was to identify phage that express pep-
tides specifically binding to different gliadin domains
and to identify and characterise the gliadin-binding
properties of the chosen individual peptides.
Results
Purification and immobilisation of gliadin proteins
Gliadin was semi-purified from commercially obtained
gluten (Sigma) and from whole wheat grains as a com-
parison. Several proteins of varying molecular weights
were obtained from both sources (Figure 1). Using a
commercial gliadin ELISA kit it was confirmed that the
included anti-gliadin antibodies reacted with the semi-
purified gliadin fractions. As a control, gliadin-like pro-
teins (avenins) were extracted from oat grains but the
commercial antibodies did not, as expected, react with
the oat proteins (data not shown). The gliadin prepara-
tion was finally dissolved in either 0.1 M NaHCO3 or in
2 M urea, added to microtiter plate wells and allowed to
bind to plastic. After washing, bound gliadin molecules
were quantified with an ELISA assay using the commer-
cial human anti-gliadin IgG antibodies. This confirmed
that gliadins indeed had been immobilised to the wells
and that the antibodies used recognised both the gliadin
NaHCO3- and urea-treated molecules. However, the
detection limit was reduced about 5 times when gliadins
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were dissolved in urea indicating that the 3D structure
of the antibody-binding sites of gliadin were affected by
the buffer used (Figure 2).
Selection of peptides specifically binding to gliadin
peptides by biopanning
Two different phage display libraries, one displaying 12-
mer and one displaying 7-mer random peptides, were
panned to the immobilised gliadin. In each panning
round unbound phage were removed by washing.
Remaining bound phage were eluted and allowed to
infect E. coli cells. After single plaque amplification and
phage purification a new round of panning was per-
formed with the obtained phage population. Panning
was done both with gliadin dissolved in urea and in
NaHCO3. Since electrostatic binding of the phage to the
target protein weakens with increasing ionic strength,
which in turn influences the specificity of the interaction
[39], different buffers with different ionic strengths were
tested prior the actual panning experiments. After opti-
mising parameters like binding, washing, and elution
conditions, a protocol was developed in which the
phage recovery increased after each round of panning.
Typically five rounds of panning were done. After the
final plating, 100 plaques were randomly picked and
amplified separately. Phage DNA was then isolated from
each isolate, the oligonucleotide inserts sequenced and
the deduced amino acid sequence of the displayed pep-
tide determined.
In total, inserted individual oligomer sequences from
approximately 1000 phage, selected under a number of
different panning conditions, were obtained. Although
identical sequences were frequently picked up in inde-
pendent experiments, altogether more than 160 unique
sequences encoding peptides with potential gliadin bind-
ing activities were identified (data not shown). All
obtained sequences originated from the 12-mer library.
Many of the peptides could be crudely divided into sub-
groups based on sequence similarities. However, more
than a half of the peptides showed no obvious sequence
similarities to each other. This indicates that the pep-
tide-targeted surfaces in the used gliadin preparations
are much diversified.
As a control, panning against microtiter plates coated
with BSA was performed. Peptides identified in this way
were denoted control peptides (CP). Altogether, five dif-
ferent CP sequences were identified. There were no
sequence similarities between these control sequences
and any of the gliadin binding sequences.
Rescuing selected phage clones
In order to confirm that the selected phage clones inter-
acted with gliadin proteins, nine different phage popula-
tions that had repeatedly been picked up in different
panning experiments were chosen. Together, these nine
sequences represent 89% of all identified gliadin-binding
sequences (Table 1). The remaining approximately 150
sequences thus were found in only 11% of the cases.
From each of the nine populations 1 × 1011 pfu were
incubated with the gliadin-coated microtiter wells. In
addition, a phage population representing a non gliadin-
binding control sequence (CP31) was incubated with the
gliadin-coated microtiter wells. After extensive washing,
remaining phage were eluted and counted. This showed
that phage carrying the CP31 control peptide were very
poor binders, as only 1 × 104 pfu were rescued from
this population under the conditions used. From the
phage that carry specific peptides, on the other hand
more than 1 × 108 pfu were rescued (Figure 3). Phage
150
100
75
50
37
25
20
15
1            2          3          4           5          6 kDa
Figure 1 SDS-PAGE separation of gliadin and gliadin-like
proteins. Lane 1: molecular weight standard; lane 2: gliadin purified
from gluten (Sigma) in 40% ethanol; lane 3: gliadin purified from
Triticum aestivum cv. Surco in 40% ethanol; lane 4: gliadin purified
from Triticum aestivum cv. Surco in 2 M urea; lane 5: gliadin-like
(avenins) proteins purified from Avena sativa cv. Leon in 40%
ethanol; lane 6: avenins purified from Avena sativa cv. Leon in 2 M
urea.
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Figure 2 Quantification of immobilised semi-purified gliadin
(Sigma). Microtiter wells were coated with increasing amounts of
gliadin (ng) as indicated on X-axis. Commercial anti-gliadin
antibodies bound to the coated gliadin were quantified by adding
a secondary AP-tagged goat anti-human IgG antibody and
measured as absorbance at 405 nm (Y-axis).A. Gliadin dissolved in
100 μl 0.1 M NaHCO3 (pH 8.6).B. Gliadin dissolved in 100 μl 2 M
urea.Error bars indicate variation between two different experiments.
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P61, which was the was most frequently picked up in
the panning experiments, displayed the highest relative
binding affinity, while phage carrying peptides P21, P22,
P62, P64, P65 and P67 showed intermediate affinities
(Figure 3).
Selected phage clones hinder anti-gliadin antibody
binding to gliadin
To investigate if the selected, gliadin-interacting phage
could hinder antibody binding to gliadin, 1 × 1011 pfu of
the same nine phage populations as in the previous experi-
ment (Figure 3) were added to wells coated with 10 ng
gliadin. The CP31 phage population as well as a buffer
solution without phage were used as controls. To investi-
gate if the peptides not only interfered with commercial
anti-gliadin antibody binding but also interfered with the
interaction between gliadin and antibodies present in
serum from individuals with suspected CD, after extensive
washing, pooled sera from 20 individuals was added.
Again, the amount of bound antibody was quantified by
adding an AP-labelled secondary anti-human IgG anti-
body. This showed that the greatest signals i.e. most anti-
bodies bound were from the controls where no gliadin-
blocking peptides were present (Figure 4). On the other
hand, all the selected phage populations blocked the signal
to various extents, indicating that the peptides displayed
on the phage interfered with the anti-gliadin antibody-glia-
din interaction. Wells incubated with phage populations
P61 and P64 gave the lowest signal indicating, in agree-
ment with the previous experiment (Figure 3), that these
were the most efficient gliadin binders.
Gliadin binding of synthetic peptides
Since all selections were based on phage-displayed pep-
tides, we investigated whether synthetic peptides, with
the same sequence as those in the selected phage, main-
tained the gliadin-binding ability also when removed
from the steric context of the phage surface. Peptides
based on the most frequently identified sequences, P64,
P61 and P22 (Table 1) as well as the non-specifically
binding control peptide CP31, were synthesised. A bio-
tin label was added at the N-terminus of all the peptides
to facilitate detection. To test peptide-gliadin binding,
different concentrations of gliadin proteins (110 ng)
were immobilised in microtiter wells and 1015 molecules
(1.67 nmoles) of the synthetic peptides were added to
the wells. After incubation and extensive washing to
remove unbound peptides the biotin signals from the
remaining peptides were quantified. The results showed
Table 1 Most frequently identified phages and peptides
in this study
Peptide Sequence Frequency (%)
P61 W H W R N P D F W Y L K 22.5
P64 W H W T W L S E Y P P P 21.5
P22 L E T S K L P P P A F L 12.5
P62 W H W S Q W L S G S P P 8.5
P63 W H R T P Q F W A F P W 7
P21 S V S V G M K P S P R P 5
P66 W H K T P W F W P T N L 5
P67 W H W S W Q P Q R H S P 4
P65 W H W Q Y T P W W R G S 3
Sum 89
CP31 (control) A Y Y P Q N H K S N A E NA
3.0x108
2.5x108
2.0x108
1.5x108
1.0x108
5.0x107
0
     P21 P22 P61 P62 P63  P64 P65 P66 P67 CP31
pfu
Figure 3 Phage recovery experiment. Different phage (1 × 1011
pfu), as indicated on the X-axis, were incubated in gliadin (10 ng)
coated microtiter wells. After washing, bound phage were eluted
and counted. The Y-axis shows the number of recovered phage
given as plaque forming units (pfu). The experiment was replicated
three times. Error bars indicate the variation between the
experiments.
 P21   P22    P61   P62   P63    P64   P65   P66   P67  CP31 control
1.0
0.8
0.6
0.4
0.2
0.0
OD units
Figure 4 Gliadin-anti-gliadin antibody interaction in the
presence of peptide-displaying phage. The Y-axis shows different
phage displaying peptides tested. Phage (1011 pfu/ml) were added
to microtiter wells coated with 10 ng gliadin. After incubation and
extensive washing, pooled sera from patients with suspected CD
were added. The amount of bound antibody was determined by
adding a secondary AP-tagged goat anti-human IgG antibody, and
measured as absorbance at 405 nm (Y-axis).
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that P61 had the highest binding activity, P64 somewhat
weaker, and P22 the weakest binding activity (Figure 5),
corroborating the experiments with the phage carrying
peptides (Figure 3 and 4). No activity at all could be
detected from the incubations with the control peptide.
As expected, the number of bound peptides increased
with increasing gliadin concentrations (Figure 5).
Gliadin-blocking activity of selected synthetic peptides
To confirm that the free peptides could block anti-gliadin
antibody-gliadin interactions with similar efficiency as the
phage-displayed peptide, 1.67 nmoles (1015 molecules) of
the synthetic peptides were mixed with increasing con-
centrations of gliadin (0.25-100 ng), followed by an incu-
bation of the peptide/gliadin mixture in anti-gliadin
antibody coated wells. After incubation and washing
away unbound gliadin and peptides, a secondary antibody
binding to the solid phase antibody-antigen complex was
added, and the amount of complex quantified by means
of the tag on the secondary antibody. This showed that
the P64 and P61 peptides interfered with or blocked anti-
genic sites on the gliadin molecules, since fewer signals
were obtained with these peptides than with P22, CP31
and the no peptide control (Figure 6). Furthermore, the
blocking effect was visible in the whole concentration
range (0.5-100 ng) of gliadin tested (Figure 6).
To further test the binding efficiencies of the peptides,
two best peptides P61 and P64 and the control peptide
CP31 were diluted in several steps and incubated with 1
ng of gliadin followed the incubation in the antibody-
coated microtiter wells. This showed that as little as 109
peptide molecules (0.167 pmoles) could interfere with
the anti-gliadin antibody-gliadin interactions to a level
detectable in the experiment (Figure 7).
Dot blot and western blot analysis
To further verify the physical interaction of the peptides
and gliadin, and to elucidate if the peptides preferentially
bind to specific proteins in the semi-purified gliadin
ng gliadin1                 3                5               10
0.25
0.20
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0.10
0.05
0.00
P61
P61/64
P64
P22
OD units
Figure 5 Binding of synthetic peptides to gliadin proteins.
Microtiter wells were coated with increasing amounts of gliadin
(ng) as indicated on the X-axis. Afterwards 1015 molecules (1.67
nmoles) of biotinylated peptides, P61, P64, or P22 were added to
the wells. Bound peptides were quantified as absorbance units at
405 nm (OD units) by means of the biotin adduct as described in
Methods. P61/64 is a 1:1 mixture of peptides P61 and P64.
2.0
1.5
1.0
0.5
0.0
P61
P64
P22
CP31
Buffer
0 . 2 5    1      3       5      1 0     3 0     5 0    1 0 0
OD units
ng
gliadin
Figure 6 Inhibition of gliadin/anti-gliadin antibody binding by
selected synthetic peptides. Increasing amounts of gliadin in ng
(as indicated on the X-axis) were incubated with 1.67 nmoles of
biotin-labelled synthetic peptides (1015 molecules) for 1 h at room
temperature. Buffer (0.1 M NaHCO3) without peptides was used as a
control. The mixes were then added to anti-gliadin monoclonal
antibody-coated wells provided with the Immunotech gliadin ELISA
kit. After incubation for 1 h at room temperature, gliadin-antibody
complexes immobilised in the wells were quantified as described
(see Methods) and given as absorbance units at 450 nm (Y-axis).
Error bars show the variation in three different experiments.
1015                   109 105
0.5
0.4
0.3
0.2
0.1
0.0
P61
P64
CP31
OD units
molecules
gliadin
Figure 7 Concentration dependency of peptide gliadin/anti-
gliadin antibody binding inhibition. Gliadin was diluted to 1 ng/
ml and mixed with 1.67 nmoles, 0.167 pmoles, and 0.0167 fmoles
(1015, 109, and 105 molecules respectively) of peptides P61, P64, and
CP31. Afterwards the gliadin/peptides mixes were added to anti-
gliadin, monoclonal antibody-coated wells and incubated for 1 h.
The formed gliadin/antibody complexes immobilised in the wells
were quantified as described (see Methods) and given as
absorbance units at 450 nm (Y-axis).
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fraction used here, dot blot and western blot experiments
were performed. In the dot blot experiments, increasing
concentrations (25 ng/μg) of the gliadin preparation were
spotted on filters. The filters were then incubated with
either of the P22, P61, P64 or CP31 peptides, and subse-
quently washed. Bound peptides were quantified with an
anti-biotin AP-labelled antibody recognising the biotin
tag on the peptides. The results from these analyses again
confirmed that the peptides physically interacted with
gliadin and as previously, the P61 peptide had the highest
binding activity, followed by the P64 peptide. No binding
could be detected with the P22 and the CP31 peptides
(Figure 8).
In the western blot experiments, gliadin proteins were
separated on SDS-PAGE gels and blotted to nitrocellu-
lose membranes. By using the P61, P64, P22 or CP31
peptides as probes and again detecting peptides bound
to the filter by means of the secondary AP-labelled anti-
biotin antibody it became clear that, as in the dot blot
experiments, P61 and P64 showed the strongest binding
(Figure 9). Both these peptides interacted with proteins
in the 29-30 kDa range, and in addition P61 also bound
to proteins between 49-70 kDa. Thus, the two peptides
have overlapping but distinct binding specificities. A
similar pattern was obtained both when analysing the
gliadin extracted from Sigma gluten and gliadin
extracted from wheat (Figure 9).
Discussion
Wheat gluten consists of a complex mixture of proteins
that based on their common structures can be divided
into three groups: a high molecular weight (HMW)
group that contains HMW-glutenin subunits with Mr
~67-88 kDa; a medium molecular weight (MMW)
group containing ω-gliadin proteins with Mr ~34-55
kDa; and a low molecular weight (LMW) group with a/
b-, g-gliadins and LMW-glutenin subunits with Mr ~28-
39 kDa [40-43]. Several of the glutenin and gliadin pro-
teins contain repeated proline and glutamine residues,
especially QQPFP and PQQPF motifs, which are resis-
tant to complete digestion by gastric and pancreatic
enzymes [18]. The repeats can trigger immune response
and appear to be especially important for the specific
gluten peptide recognition by CD4+ T cells [17,44]. Pre-
viously, it was shown that phage display might be a use-
ful technology to identify peptides that bind to gliadin
residues, although no sequences were shown [38]. Here,
we extended this work to include several different glia-
din proteins to increase the probability of identifying
phage that bound to reactive surfaces (Figure 1). Gluta-
mine residues within gliadin can be deamidated by tis-
sue transglutaminase (tTG), which will further enhance
the pathologic immune response [45]. If blocking pep-
tides efficiently inhibit recognition of gliadin by tTG
they will most probably aid in limiting the development
of T cell epitopes. In a recently published study we have
shown that when in complexes with the selected block-
ing peptides, the in vitro enzymatic modification of glia-
din by tTG was reduced by ~one-third [46].
There is no cure for CD. The only available therapy is a
life-long exclusion of gluten from a diet. The variety of
bakery and pastry gluten-free products is limited and the
price is higher than their gluten containing equivalents
[47]. Moreover, these products often do not meet the
dietary requirements, as they tend to be high in fat and
   P61         P64        P22        CP31
1000
750
500
250
125
60
25
ng
gliadin
Figure 8 Dot blot analysis of peptide-gliadin binding. Different
amounts of gliadin proteins, as indicated on the Y-axis, were
spotted onto nitrocellulose strips. Each strip was incubated with
1.67 nmoles (1015 molecules) of the peptide indicated on the top of
the figure. After washing the biotin signal from the bound peptide
was developed as described.
A    B
80
49
35
29
   P61                  P64                  P22                  CP31
A    B A    B A    B
Mw (x 
1000)
Figure 9 Western blot analysis of peptide-gliadin binding. 10
μg of gliadin extracted from Sigma gluten (A) or 10 μg of gliadin
extracted from Surco wheat (B) was loaded on a polyacrylamide gel.
Separated proteins were transferred to a nitrocellulose membrane.
Each membrane was incubated with 1.67 nmoles (1015 molecules)
of the peptide indicated at the bottom of the figure. After washing
the biotin signal from the bound peptide was developed as
described.
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low in fibre as compared to gluten-containing equivalents
[47,48]. Furthermore, naturally gluten-free grains and
flours can be contaminated with gluten during fieldwork,
transport, processing or in a store if grains are kept in
open containers [49,50]. One alternative strategy would
be to neutralise minor contaminations in e.g. oat, rice or
maize products by mixing in molecules that block or
digest the harmful motifs in gluten molecules [25]. Glu-
ten-blocking peptides, like the ones described in this
work, could perhaps be one way to detoxify disease-indu-
cing gluten peptides in the future.
By using a number of different panning conditions
and gliadin proteins dissolved in either urea or NaHCO3
a large number of phage displaying different peptide
sequences has been identified. To investigate if the iden-
tified peptides could interfere with the human anti-glia-
din antibody and gliadin interaction, we mixed peptide-
carrying phage with gliadin and pooled sera originating
from patients with suspected CD. In that way we
demonstrated that the phage indeed inhibited interac-
tions between gliadin and human anti-gliadin antibody
(Figure 4). For these analyses we used patient sera from
a biobank. The sera were selected for having high titers
of anti-gliadin antibodies (≤100 U/ml) and positive or
high titers of anti-transglutaminase IgA antibodies,
although we had no specific information regarding the
patients’ clinical diagnosis. The production of anti-glia-
din antibodies is not specific to coeliac disease since
slightly elevated serum concentrations are also found in
other gastrointestinal disorders and even in normal indi-
viduals [51,52]. However, the levels of anti-gliadin anti-
bodies in patients without coeliac disease seem to be
much lower compared to our selected serum samples
[53]. As our patients had high levels of both anti-gliadin
and anti-transglutaminase antibodies it is likely that they
had CD.
To verify whether the peptides, also when removed
from the context of the phage, could interact with glia-
din, we synthesised three peptides that were repeatedly
identified in independent panning experiments and one
control peptide that only interacted with BSA. We
could then show that two of the peptides, P61 and P64
indeed interfered with the gliadin anti-gliadin antibody
binding (Figure 6 and 7). In this case, two different
monoclonal anti-gliadin antibodies provided by a com-
mercial kit were used. In addition, by means of the bio-
tin label attached to the peptides, we also showed in
western blot experiments that P61 and P64 could bind
to several of the separated and immobilised gliadin
proteins (Figure 9).
Since we have so far only studied the nine gliadin-
binding peptides that were most often picked up, we
still have more than 150 additional peptides to test.
Most likely, several of these peptides will also bind to
gliadin. Since all individual peptides will bind to differ-
ent sites on the gliadin complex, pooling of several dif-
ferent peptides could generate synergistic effects, and it
should be possible to develop this concept in the direc-
tion of a drug against CD. However, many more experi-
ments have to be performed, addressing issues like the
stability of the peptide-gliadin interaction in chemical
conditions likely to be encountered in the gut or in food
preparation, the characterization of the actual binding
sites in more detail, and the interaction with digestive
enzymes and tissue transglutaminase etc. before any
conclusions about the usefulness of these peptides in a
therapeutic situation can be drawn.
Conclusions
Finally, there are still several unanswered questions on
the role of gliadin in the development of CD. Some of
the gliadin-binding peptides presented here, labelled in
different ways, could provide valuable tools for research-
ers in the field of CD to study localisation and uptake of
various gliadin peptides in the small intestine.
Methods
Gliadin preparation
Gliadin was extracted from gluten (Sigma Aldrich, Stock-
holm, Sweden) as described [41] with some modifications.
Essentially, 1.5 g gluten was dissolved in 20 ml 25 mM
Na2SO3, vortexed 15 min at room temperature (RT) and
centrifuged at 5000 g for 5 min. The pellet was washed in
20 ml 25 mM Na2SO3 and suspended in 70% ethanol by
incubating at 70°C for 30 min with vortexing every 5 min.
Undissolved material was eliminated by centrifugation,
and the supernatant was incubated on ice for 2 h to preci-
pitate the high molecular weight glutenin, which was
eliminated by centrifugation for 10 min at 4°C. Subse-
quently the supernatant was mixed with 6 M NaCl in 70%
ethanol to a final concentration of 256.67 mM NaCl and
centrifuged for 10 min at 4°C. The supernatant that con-
tained the gliadin-LMW-glutenin enriched fraction (in
70% ethanol and 256.67 mM NaCl) was stored at -80°C
until further use. In addition, seeds (ca 1 g) from Surco
(wheat) and Leon (oat) varieties were ground and dissolved
in 1 ml of 40% ethanol. The samples were centrifuged at
5000 g for 10 min and the supernatant stored at -20°C.
Immobilisation of gliadin proteins
Gliadin (1-100 ng) prepared as above and diluted in 0.1
M NaHCO3 (pH 8.6) was incubated in 96-well microtiter
(EIA/RIA) plates (Corning Inc. Corning, NY) at 4°C for
16 h. The amount of immobilized gliadin was quantified
using the Anti-Gliadin IgG Kit (Biohit Oyi, Helsinki, Fin-
land) according to the producer’s protocol where the
“positive control” patient serum provided in the kit was
used as the primary anti-gliadin antibody, and labelled
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polyclonal anti-human IgG (goat) antibody was used as
the secondary antibody. The positive signal was devel-
oped using the p-nitrophenyl phosphate solution (NPP)
reagent and measured as absorbance at 405 nm.
In vitro panning of phage display peptide library
The Ph.D. -12™ Phage Display Peptide Library kit,
including E. coli ER 2738 host strain, was purchased
from New England BioLabs (Beverly, MA). Selection of
peptides was carried out according to the manufacturer’s
instructions. 25 μg of gliadin in 0.1 M sodium bicarbo-
nate (pH 8.6) was coated onto 96-well microtiter plates
(EIA plates) at 4°C overnight. Remaining surfaces in the
wells were then blocked for 2 h at 4°C with 5% BSA
diluted in 0.1 M sodium bicarbonate (pH 8.6) with
0.02% NaN3. Afterwards, approximately 1 × 10
11 plaque
forming units (pfu) of phage were diluted in 100 μl of 1
× LIB (Low Ionic Strength buffer, 10 mM sodium phos-
phate, pH 6.0) with 0.5% BSA and 0.1% Tween-20, and
incubated with gliadin for 1 h at RT with gentle shaking.
The same procedure was used in negative control pan-
nings but in this case the wells were just coated with
BSA (no gliadin present). After phage incubation, the
wells were washed ten times with LIB with 0.5% Tween-
20. Unbound phage were discarded. Bound phage were
eluted with 0.2 M glycine-HCl, 1% BSA (pH 2.2) and
amplified by infecting E. coli ER2738 host cells. After
4.5 h of growth at 37°C phage were removed from bac-
terial cells by centrifugation. The phage present in the
supernatant were precipitated by adding 1/6 volume of
PEG/NaCl solution (20% w/v polyethylene glycol-8000;
2.5 M NaCl), and incubated for 16 h at 4°C. The preci-
pitate was resuspended in a small volume of LIB, and
amplified elutes were titrated to determine phage con-
centration. Typically, the panning procedure was
repeated five times after which phage were plated and
random plaques were picked. After amplification, phage
were purified by precipitation in PEG/NaCl followed by
resuspension in 1/50 volume of the original volume in 1
× LIB with 0.02% NaN3 and stored in aliquots at 4°C.
These phage were then used in the binding specificity
and affinity experiments and for DNA extraction.
DNA sequencing
Single-stranded phage DNA was isolated by incubation
in iodide buffer (4 M NaI, 1 mM EDTA in 10 mM Tris-
HCl, pH 8.0) to denature the phage coat protein.
Released DNA was then precipitated in 70% ethanol.
Purified DNA was sequenced by Microgen Inc. (Seoul,
Korea) and MWG Biotech AG (Martinsried, Germany).
Phage recovery experiment
Coated and blocked (as described above) microtiter
plate wells were washed three times with 0.1% LIBT
(LIB buffer with 0.1% Tween-20). Selected phage were
serially diluted in 0.1% LIBT buffer and 100 μl was
added to the wells. After addition of 1% BSA the wells
were incubated for 1 h at 37°C. Control wells were incu-
bated in the same buffer but without phage. Next, the
wells were washed six times with 0.5% LIBT to remove
the unbound phage. The remaining phage were eluted
with glycine-HCl (pH 2.2) in 1% BSA and phage titers
were determined.
Patient antisera
The serum samples were obtained from a biobank at the
immunological laboratory, Sahlgrenska University hospi-
tal, Gothenburg, Sweden. The samples were selected for
high titers (≤100 U/ml) of anti-gliadin IgA antibodies
and for positive or high titers of anti-transglutaminase
IgA antibodies. The serum samples were prepared
according to standard procedure, i.e. blood was drawn
into unprepped tubes and serum was collected by cen-
trifugation at 3000 g. Serum was diluted (1:500) with
dilute buffer (same as dilute buffer from Anti-Gliadin
IgG kit). The serum used here was a pool from 20 dif-
ferent anonymous patients.
Phage ELISA
Since the phage display was done on a mixture of differ-
ent gliadin proteins, potentially a lot of different pep-
tides could bind to the coated proteins. To block out as
many peptides as possible in the same experiment
pooled polyclonal patient sera isolated from 20 different
patients with suspected CD were used.
Microtiter plate wells were coated with 100 μl of
gliadin proteins (0-100 μg/ml) dissolved in 0.1 M
NaHCO3 (pH 8.6) and incubated overnight at 4°C.
Subsequently, the wells were blocked with 200 μl of
blocking buffer (5% BSA in 0.1 M NaHCO3, pH 8.6;
with 0.02% NaN3) for 2 h at 4°C and washed three
times with 0.1% LIBT (LIB with 0.1% Tween-20).
Phage (1 × 1011) carrying different peptide sequences
in 100 μl blocking buffer were transferred to the
coated wells and incubated at 37°C for 1 h. Unbound
phage were removed by washing six times with 0.5%
LIBT (1 × LIB buffer with 0.5% Tween-20). After this,
100 μl pooled patient antiserum (diluted 1:500 with
dilution buffer from the Anti-Gliadin IgG kit, Biohit
Oyi, Helsinki, Finland) was added. After the 30 min
incubation at RT the wells were washed four times
with 1 × ELISA washing buffer (Phosphate Buffered
Saline, pH 7.2, 0.05% Tween-20, Biolegend, San Diego,
CA). For detection, 100 μl of AP-linked, goat anti-
human IgG (Invitro/Biolabs, Beverly, MA) diluted
(1:4500) with dilution buffer from the Anti-Gliadin
IgG kit was added to the wells and incubated for 30
min at RT. After washing four times with 1 × ELISA
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washing buffer, 100 μl of Nitrophenyl Phosphate Diso-
dium substrate solution (NPP) (Invitrogen, Madison,
WI) was added and incubated for 30 min at RT.
Finally, the signal was detected by measuring absor-
bance at 405 nm in a microplate reader.
Peptide synthesis
Four peptides, denoted P61, P64, P22 and CP31 were
synthesized at >95% purity by Bio-Synthesis Inc. (Lewis-
ville, TX), with biotin added to the N terminus. Peptides
were dissolved in 150 μl DMF (dimethylformamide) and
diluted to 1 ml with 0.05 M phosphate buffer containing
0.15 M NaCl, pH 7.4 (Peptide Dilution Buffer, PDB) to a
final concentration of 16.7 μM. Aliquots were stored at
-20°C until further use.
Binding of synthetic peptides to gliadin proteins
100 μl, corresponding to 1.67 nmoles (1015 molecules)
of the synthesized peptides were added to gliadin-coated
microtiter wells (1-100 ng) and was incubated in 0.1 M
NaHCO3 (pH 8.6) for 1 h at 37C.
The wells were washed four times with 1 × ELISA
buffer (diluted from 20 x ELISA washing buffer, Biole-
gend, San Diego, CA) after which 100 μl anti-biotin AP-
linked antibody (http://www.cellsignal.com) diluted
1:3000 was added. After the 30 min incubation at RT,
and washing (four times) with 1 × ELISA buffer, 200 μl
of 1 × NPP substrate (Invitrogen, Carlsbad, CA) was
added to the wells. After the 30 min incubation at RT
in the dark 100 μl of stop solution was added, the plates
were shaken, and the signal was read at 405 nm.
Inhibition of gliadin-anti-gliadin antibody binding by
selected synthetic peptides
Gliadin was prepared as described and diluted to a final
concentration of 100, 50, 30, 10, 5, 3, 1 and 0.5 ng/ml in
200 μl dilution buffer provided in the Immunotech
ELISA kit (Radiová 1, Prague, Czech Republic). Each
gliadin dilution was incubated with 1.67 nmoles (1015
molecules) of the synthetic peptides P64, P61, P22,
CP31 and a control with only 0.1 M NaHCO3 buffer at
RT for 1 h. The gliadin/peptide mixtures were then
added to microtiter wells coated with two different anti-
gliadin monoclonal antibodies provided with the Immu-
notech Gliadin ELISA kit. As internal calibrators, 0 and
9 ng gliadin solutions were added to separate wells.
Wells with the different mixes were incubated for
another hour at RT. Afterwards bound gliadins were
quantified using a polyclonal antibody (horseradish per-
oxidase conjugate) that binds to the solid phase anti-
body-antigen complex. Bound secondary antibody was
quantified using TMB substrate (tetramethylbenzidine)
as described in the kit. Positive signals were given as
absorbance units at 450 nm.
Concentration dependency of peptide gliadin-anti-gliadin
antibody binding inhibition
Gliadin was diluted to a final concentration of 1 ng/ml
in 200 μl 0.1 M NaHCO3 dilution buffer as described
and mixed with 1.67 nmoles, 0.167 pmoles, and 0.0167
fmoles (1015, 109, 105 molecules) respectively of the bio-
tin-labelled synthetic peptides P61, P64, and CP31, dis-
solved in 0.1 M NaHCO3 buffer. After incubation for 1
h at RT the gliadin/peptide mixtures were then added
to the anti-gliadin antibody coated microtiter wells and
incubated for another hour. Secondary antibody was
thereafter added and quantified as absorbance units at
450 nm as described above.
Dot blot assay
4 μl of serial dilutions of gliadin proteins in 0.1 M
NaHCO3 (pH 8.6) were spotted onto 0.45 μm nitrocellu-
lose membranes, air dried, and subsequently quenched by
soaking into 5% non-fat milk in PBS overnight at 4°C.
Blocking solution was removed by washing the mem-
branes with PBST (137.9 mM NaCl, 1.47 mM KH2PO4,
8.1 mM Na2HPO4, 2.68 mM KCl, 0.05% Tween-20, pH
7.4). Biotinylated blocking peptides were diluted in PBS
and incubated with the membranes for 3 h at RT with
gentle shaking. After subsequent washing with PBST
(four times), anti-biotin AP-linked antibody (diluted
1:3000 with dilute buffer, 50 mM PBS, pH 7.2, 0.05%
Tween-20) was incubated with the membranes for 2 h
with gentle shaking. Finally, the membranes were washed
four times with PBST-0.05%, once with PBS and the AP-
substrate was added. The images were developed with
immune-star™ AP chemiluminescent protein detection
system (Bio-Rad Laboratories, Sundbyberg, Sweden).
Western blot analysis
Gliadin proteins were separated during SDS-PAGE on
12% Tris-glycine gels. The separated proteins were
transferred in transfer buffer (48 mM Tris, 38.6 mM
glycine, 1.6 mM SDS, 20% methanol) to nitrocellulose
membranes (Amersham/Biosciences, Sweden) for 2.5 h
at 90 mA in a semi-dry electroblotting unit (Z34050-2,
Sigma, Stockholm, Sweden). After the protein transfer
the membranes were washed with washing buffer (PBS,
0.05% Tween-20) and blocked with 3% BSA in PBS
overnight at 4°C. For development of the biotin signal,
the same protocol as in the Dot blot assay was used.
The study was approved by the Human Research
Ethics Committee of the Medical Faculty, Gothenburg
University, Gothenburg, Sweden with the permission
number 144-06. The serum samples were obtained from
a biobank at the immunological laboratory, Sahlgrenska
University hospital, Gothenburg. Biobank samples were
selected for high titers of gliadin-specific IgA antibodies
and for positive or high titers of anti-tTG antibodies.
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According to the Swedish biobank law, the serum sam-
ples were completely impersonalized, which means that
the samples cannot be linked to any patient, his or her
personal data, or to the clinical evaluation.
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